Celanese Corporation Reports Full Year 2022 and Fourth Quarter Earnings

Rhea-AI Summary

Celanese Corporation (NYSE: CE) reported record GAAP diluted EPS of $17.41 and adjusted EPS of $15.88 for 2022, achieving net sales of $9.7 billion, up 13% from 2021. Despite significant raw material and energy cost inflation of over $1.2 billion, the company offset these pressures through pricing increases. The acquisition of DuPont's Mobility & Materials business significantly contributed to Celanese's performance. In Q4 2022, GAAP diluted EPS was $7.03, with adjusted EPS of $1.44, reflecting challenges from destocking and demand fluctuations, particularly in Asia. The company anticipates improved earnings in Q1 2023, projecting adjusted EPS between $1.50 to $1.75.

Positive

• Record GAAP diluted EPS of $17.41 for 2022.
• Net sales reached $9.7 billion, a 13% increase year-over-year.
• Successful acquisition of DuPont's Mobility & Materials business enhances market position.
• Q1 2023 adjusted EPS projected between $1.50 to $1.75, signaling potential earnings growth.

Negative

• Fourth quarter faced challenges including accelerated destocking and poor demand in Asia.
• Acetyl Chain segment reported a 3% decline in net sales versus 2021 due to volume decreases.

DALLAS--(BUSINESS WIRE)-- Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today reported highest-ever GAAP diluted earnings per share of $17.41 and second-highest ever adjusted earnings per share of $15.88 for full year 2022. The Company generated record net sales of $9.7 billion in the year, an increase of 13 percent over the prior record set in 2021. Full year net sales reflected increases in pricing and volume of 11 percent and 6 percent over 2021, respectively. The Company delivered year over year pricing growth and productivity across both business segments to largely offset over $1.2 billion in raw material, energy, and supply chain cost inflation over 2021. As a result, the Company reported 2022 consolidated operating profit of $1.4 billion and adjusted EBIT of $2.2 billion. During the year, the Company generated record operating cash flow of $1.8 billion and free cash flow of $1.3 billion. Celanese returned $297 million in cash to shareholders via dividends in 2022.

On November 1, 2022, the Company successfully completed the acquisition of the Mobility & Materials (M&M) business of DuPont, acquiring a broad portfolio of engineered thermoplastics and elastomers, industry-renowned brands and intellectual property, global production assets, and a world-class organization. The acquisition establishes Celanese as the preeminent global specialty materials company. Full year 2022 financial results reflect the contribution of M&M performance in November and December.

The difference between GAAP diluted earnings per share and adjusted earnings per share for 2022 was primarily due to an income tax provision for U.S. GAAP that was a benefit for full year 2022 as a result of non-recurring internal restructuring transactions related to the M&M acquisition. The impact of the beneficial tax recognition more than offset the impact of costs related to the M&M acquisition, including approximately $267 million in M&A-related costs, and $158 million in net interest expense incurred prior to transaction closing and certain fees related to debt issued.

Celanese also reported fourth quarter GAAP diluted earnings per share of $7.03 and adjusted earnings per share of $1.44. The Company generated operating cash flow of $541 million and free cash flow of $395 million in the quarter.

"Our team delivered resilient performance despite an exceptionally challenging end to 2022 including accelerated destocking, poor sequential demand in Asia due to COVID, challenging competitive dynamics in Europe, and the impact of Winter Storm Elliott," said Lori Ryerkerk, chair and chief executive officer. "Our 2022 adjusted earnings per share performance was within 12 percent of our all-time high delivered in 2021 and 44 percent higher than our next best year. Despite the impact of elevated volatility across a number of external dynamics, our Celanese team continues to execute our business models and demonstrate a long-term underlying lift in the earnings power of the company."

Fourth Quarter 2022 Financial Highlights:

	Three Months Ended
	December 31, 2022				September 30, 2022				December 31, 2021
	(unaudited)
	(In $ millions, except per share data)
Net Sales
Engineered Materials		1,237				929				707
Acetyl Chain		1,135				1,397				1,590
Intersegment Eliminations		(24	)			(25	)			(22	)
Total		2,348				2,301				2,275
Operating Profit (Loss)
Engineered Materials		25				114				67
Acetyl Chain		204				312				539
Other Activities		(173	)			(118	)			(89	)
Total		56				308				517
Net Earnings (Loss)		769				193				526
Adjusted EBIT(1)
Engineered Materials		138				206				113
Acetyl Chain		242				349				574
Other Activities		(78	)			(45	)			(35	)
Total		302				510				652
Equity Earnings and Dividend Income, Other Income (Expense)
Engineered Materials		35				70				30
Acetyl Chain		30				34				36
Operating EBITDA(1)		453				607				745
Diluted EPS - continuing operations	$	7.03			$	1.76			$	4.83
Diluted EPS - total	$	7.03			$	1.75			$	4.79
Adjusted EPS(1)	$	1.44			$	3.94			$	4.91
Net cash provided by (used in) investing activities		(10,713	)			(143	)			(1,286	)
Net cash provided by (used in) financing activities		1,944				8,600				(99	)
Net cash provided by (used in) operating activities		541				467				584
Free cash flow(1)		395				325				415

	Year Ended December 31,
	2022				2021
	(unaudited)
	(In $ millions, except per share data)
Net Sales
Engineered Materials		4,024				2,718
Acetyl Chain		5,743				5,894
Intersegment Eliminations		(94	)			(75	)
Total		9,673				8,537
Operating Profit (Loss)
Engineered Materials		429				411
Acetyl Chain		1,447				1,875
Other Activities		(498	)			(340	)
Total		1,378				1,946
Net Earnings (Loss)		1,902				1,896
Adjusted EBIT(1)
Engineered Materials		779				571
Acetyl Chain		1,609				2,056
Other Activities		(217	)			(154	)
Total		2,171				2,473
Equity Earnings and Dividend Income, Other Income (Expense)
Engineered Materials		207				127
Acetyl Chain		143				154
Operating EBITDA(1)		2,617				2,835
Diluted EPS - continuing operations	$	17.41			$	17.06
Diluted EPS - total	$	17.34			$	16.86
Adjusted EPS(1)	$	15.88			$	18.12
Net cash provided by (used in) investing activities		(11,141	)			(1,119	)
Net cash provided by (used in) financing activities		10,290				(1,042	)
Net cash provided by (used in) operating activities		1,819				1,757
Free cash flow(1)		1,263				1,263

____________________________
(1)	See "Non-US GAAP Financial Measures" below.

Recent Highlights:

• Completed the acquisition of Mobility & Materials on November 1, 2022.

• Announced the signing of a term sheet to form a standalone Food Ingredients joint venture (JV) in which Celanese will contribute its Food Ingredients business and Mitsui will acquire a 70 percent stake. The transaction is expected to close in the third quarter and cash proceeds will be used to pay down debt.

• Completed a strategic overhaul of the acetate flake and tow products as part of the Acetyl Chain which is expected to deliver significant margin expansion in those products in 2023.

• Completed an ultra-low capital project, at the EVA facility in Edmonton, to repurpose existing manufacturing and infrastructure assets and unlock approximately 35 percent incremental capacity to meet strong demand growth.

Full Year 2022 and Fourth Quarter Business Segment Overview

Acetyl Chain

The Acetyl Chain reported 2022 net sales of $5.7 billion, a 3 percent decrease from record net sales set in the prior year. Full year net sales reflected a 6 percent increase in pricing, 6 percent decrease in volume, and 3 percent unfavorable impact from foreign currency. As a result of commercial pricing actions, the business offset the majority of approximately $650 million in raw material, energy, and supply chain cost inflation over the prior year. In the first half of 2022, the Acetyl Chain maintained volumes across its global network by pivoting volume from Asia to incremental demand and margin in the Western Hemisphere. In the second half of the year, weaker fundamental demand was amplified by destocking, particularly across Europe and China and the Acetyl Chain took decisive actions to reduce cost and align its production to market demand. The Frankfurt VAM unit, the highest-cost facility in its global VAM network, was idled for the majority of the second half of 2022. Additionally, the Acetyl Chain intentionally idled all five of its major production units in China at different points in the fourth quarter. As a result, the Acetyl Chain generated GAAP operating profit of $1.4 billion and adjusted EBIT of $1.6 billion, at margins of 25 and 28 percent, respectively. The 2022 results reflect a resegmentation of the former Acetate Tow reporting segment into the Acetyl Chain due to the successful completion of the strategic overhaul of that business as a derivative of acetic acid.

The Acetyl Chain delivered fourth quarter net sales of $1.1 billion due to sequential pricing and volume declines of 10 percent and 9 percent, respectively. In the last two weeks of the quarter, the business proactively shut down its U.S. Gulf Coast production network in anticipation of Winter Storm Elliott, resulting in over 130 kt of lost production in addition to supply chain disruptions. Despite these challenges, the Acetyl Chain delivered fourth quarter GAAP operating profit of $204 million and adjusted EBIT of $242 million, in the upper half of the guidance range provided.

Engineered Materials

Engineered Materials delivered record net sales of $4.0 billion in 2022, a 48 percent increase over the prior year. Net sales was driven by volume and price increases of 33 percent and 23 percent, respectively, and an 8 percent unfavorable impact from foreign currency. Organic volume growth in the automotive, electronics, and medical end-markets as well as volume contributions from the Santoprene and M&M acquisitions offset the impact of underlying demand softness and destocking in the second half of the year. The Santoprene acquisition, which closed in the fourth quarter of 2021, contributed across the full year. The M&M acquisition, which closed on November 1, 2022, contributed in the last two months of 2022. Pricing across 2022 expanded significantly as a result of broad commercial initiatives, including the implementation of an energy surcharge, to mitigate nearly $600 million in raw material, energy, and supply chain cost inflation. Enhanced product mix also elevated pricing, due in part to the medical implant business returning to a pre-COVID condition in the second half of the year. Engineered Materials delivered 2022 GAAP operating profit of $429 million and adjusted EBIT of $779 million. The difference between GAAP operating profit and adjusted EBIT was due primarily to costs associated with the acquisition of M&M. Affiliate earnings contributed $202 million during the year.

Engineered Materials reported fourth quarter net sales of $1.2 billion due to a sequential volume increase of 34 percent and pricing decrease of 1 percent. Volume increased sequentially due to the impact of the M&M acquisition which was partially offset by seasonality and broad destocking. Pricing decreased as the impact of a lower energy surcharge and challenging competitive dynamics in Europe more than offset the impact of improved mix. Engineered Materials reported fourth quarter GAAP operating profit of $25 million and adjusted EBIT of $138 million which included affiliate earnings of $31 million.

Cash Flow and Tax

Celanese generated full year 2022 operating cash flow of $1.8 billion and free cash flow of $1.3 billion. Capital expenditures across the year were $543 million. Celanese returned $297 million in cash to shareholders via dividends in the year.

The tax rate for U.S. GAAP purposes was a benefit of (34) percent for full year 2022 due to deferred tax benefits related to non-recurring internal restructuring transactions related to the M&M acquisition, to centralize ownership of intellectual property with the business, and to facilitate future deployment of cash to service acquisition indebtedness. The effective tax rate for adjusted earnings was 13 percent for 2022 as certain benefits of the internal restructuring will be realized in future periods.

Outlook

"Our March order books reflect improvement in many of the recent external challenges we have seen, and we are taking action to address those which still persist," said Lori Ryerkerk. "We are confident that the back half of the first quarter will represent an inflection point and that sequential earnings improvement across our businesses will drive anticipated first quarter adjusted earnings per share of $1.50 to $1.75, inclusive of approximately $0.30 per share of M&M transaction amortization¹. We expect an upward trajectory in our quarterly earnings across 2023 as a result of demand improvement reflected in our current order books, enhancements to our businesses, and M&M synergies."

A reconciliation of forecasted adjusted earnings per share to U.S. GAAP diluted earnings per share is not available without unreasonable efforts because a forecast of Certain Items, such as mark-to-market pension gains/losses, is not practical. For more information, see "Non-GAAP Financial Measures" below.

The Company's prepared remarks related to the fourth quarter will be posted on its website at investors.celanese.com under Financial Information/Financial Document Library on February 23, 2023. Information about Non-US GAAP measures is included in a Non-US GAAP Financial Measures and Supplemental Information document posted on our investor relations website under Financial Information/Non-GAAP Financial Measures. See also "Non-GAAP Financial Measures" below.

Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 13,300 employees worldwide and had 2022 net sales of $9.7 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com.

____________________________
1	Calculated as intangible amortization from the M&M transaction divided by diluted weighted average shares outstanding

Forward-Looking Statements

This release may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in this release. These risks and uncertainties include, among other things: changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate; volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, wood pulp and fuel oil and the prices for electricity and other energy sources; the length and depth of product and industry business cycles, particularly in the automotive, electrical, mobility, textiles, medical, electronics and construction industries; the ability to pass increases in raw material prices, logistics costs and other costs on to customers or otherwise improve margins through price increases; the accuracy or inaccuracy of our beliefs and assumptions regarding anticipated benefits of the acquisition (the "M&M Acquisition") by us of the majority of the Mobility & Materials business (the "M&M Business") of DuPont de Nemours, Inc., including as a result of the performance of the M&M Business between signing and closing of the M&M Acquisition; the possibility that we will not be able to realize anticipated improvements in the M&M Business's financial performance — including optimizing pricing, currency mix and inventory — or realize the anticipated benefits of the M&M Acquisition, including synergies and growth opportunities, within the anticipated timeframe, or at all, whether as a result of difficulties arising from the operation or integration of the M&M Business or other unanticipated delays, costs, inefficiencies or liabilities; increased commercial, legal or regulatory complexity of entering into, or expanding our exposure to, certain end markets and geographies; risks in the global economy and equity and credit markets and their potential impact on our ability to pay down debt in the future and/or refinance at suitable rates, in a timely manner, or at all; diversion of management's attention from ongoing business operations and opportunities and other disruption caused by the M&M Acquisition and the integration processes and their impact on our existing business and relationships; risks and costs associated with increased leverage from the M&M Acquisition, including increased interest expense and potential reduction of business and strategic flexibility; the ability to maintain plant utilization rates and to implement planned capacity additions, expansions and maintenance; the ability to reduce or maintain their current levels of production costs and to improve productivity by implementing technological improvements to existing plants; increased price competition and the introduction of competing products by other companies; the ability to identify desirable potential acquisition or divestiture opportunities and to complete such transactions, including obtaining regulatory approvals, consistent with the Company's strategy; market acceptance of our products and technology; compliance and other costs and potential disruption or interruption of production or operations due to accidents, interruptions in sources of raw materials, transportation, logistics or supply chain disruptions, cybersecurity incidents, terrorism or political unrest, public health crises (including, but not limited to, the COVID-19 pandemic), or other unforeseen events or delays in construction or operation of facilities, including as a result of geopolitical conditions, the occurrence of acts of war (such as the Russia-Ukraine conflict) or terrorist incidents or as a result of weather, natural disasters, or other crises; the ability to obtain governmental approvals and to construct facilities on terms and schedules acceptable to the Company; changes in applicable tariffs, duties and trade agreements, tax rates or legislation throughout the world including, but not limited to, adjustments, changes in estimates or interpretations or the resolution of tax examinations or audits that may impact recorded or future tax impacts and potential regulatory and legislative tax developments in the United States and other jurisdictions; changes in the degree of intellectual property and other legal protection afforded to our products or technologies, or the theft of such intellectual property; potential liability for remedial actions and increased costs under existing or future environmental, health and safety regulations, including those relating to climate change or other sustainability matters; potential liability resulting from pending or future claims or litigation, including investigations or enforcement actions, or from changes in the laws, regulations or policies of governments or other governmental activities in the countries in which we operate; changes in currency exchange rates and interest rates; our level of indebtedness, which could diminish our ability to raise additional capital to fund operations or limit our ability to react to changes in the economy or the chemicals industry; tax rates and changes thereto; our ability to obtain regulatory approval for, and satisfy closing conditions to, any transactions described herein that have not closed; and various other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission.

Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Non-GAAP Financial Measures

Presentation

This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.

Use of Non-US GAAP Financial Information

This release uses the following Non-US GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, adjusted earnings per share and free cash flow. These measures are not recognized in accordance with US GAAP and should not be viewed as an alternative to US GAAP measures of performance or liquidity. The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin is operating margin; for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; and for free cash flow is net cash provided by (used in) operations.

Definitions of Non-US GAAP Financial Measures

• Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8 of our Non-US GAAP Financial Measures and Supplemental Information document). We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales.

• Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization.

• Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.

Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a of our Non-US GAAP Financial Measures and Supplemental Information document summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.

• Free cash flow is a liquidity measure used by the Company and is defined by the Company as cash flow from operations, less capital expenditures on property, plant and equipment, and adjusted for capital contributions from or distributions to Mitsui & Co., Ltd. ("Mitsui") related to our methanol joint venture, Fairway Methanol LLC ("Fairway").

Reconciliation of Non-US GAAP Financial Measures

Reconciliations of the Non-US GAAP financial measures used in this press release to the comparable US GAAP financial measure, together with information about the purposes and uses of Non-US GAAP financial measures, are included in our Non-US GAAP Financial Measures and Supplemental Information document filed as an exhibit to our Current Report on Form 8-K filed with the SEC on or about February 23, 2023 and also available on our website at investors.celanese.com under Financial Information/Financial Document Library.

Results Unaudited

The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.

Supplemental Information

Additional information about our prior period performance is included in our Quarterly Reports on Form 10-Q and in our Non-US GAAP Financial Measures and Supplemental Information document.

Consolidated Statements of Operations - Unaudited

	Three Months Ended
	December 31, 2022			September 30, 2022			December 31, 2021
	(In $ millions, except share and per share data)
Net sales	2,348			2,301			2,275
Cost of sales	(1,964	)		(1,755	)		(1,554	)
Gross profit	384			546			721
Selling, general and administrative expenses	(269	)		(184	)		(170	)
Amortization of intangible assets	(30	)		(10	)		(8	)
Research and development expenses	(37	)		(25	)		(23	)
Other (charges) gains, net	7			(15	)		—
Foreign exchange gain (loss), net	3			(2	)		—
Gain (loss) on disposition of businesses and assets, net	(2	)		(2	)		(3	)
Operating profit (loss)	56			308			517
Equity in net earnings (loss) of affiliates	31			73			36
Non-operating pension and other postretirement employee benefit (expense) income	(57	)		25			(7	)
Interest expense	(168	)		(154	)		(21	)
Refinancing expense	—			—			—
Interest income	33			34			1
Dividend income - equity investments	30			30			33
Other income (expense), net	5			5			(2	)
Earnings (loss) from continuing operations before tax	(70	)		321			557
Income tax (provision) benefit	840			(127	)		(27	)
Earnings (loss) from continuing operations	770			194			530
Earnings (loss) from operation of discontinued operations	(1	)		—			(3	)
Income tax (provision) benefit from discontinued operations	—			(1	)		(1	)
Earnings (loss) from discontinued operations	(1	)		(1	)		(4	)
Net earnings (loss)	769			193			526
Net (earnings) loss attributable to noncontrolling interests	(2	)		(2	)		(2	)
Net earnings (loss) attributable to Celanese Corporation	767			191			524
Amounts attributable to Celanese Corporation
Earnings (loss) from continuing operations	768			192			528
Earnings (loss) from discontinued operations	(1	)		(1	)		(4	)
Net earnings (loss)	767			191			524
Earnings (loss) per common share - basic
Continuing operations	7.08			1.77			4.86
Discontinued operations	(0.01	)		(0.01	)		(0.04	)
Net earnings (loss) - basic	7.07			1.76			4.82
Earnings (loss) per common share - diluted
Continuing operations	7.03			1.76			4.83
Discontinued operations	—			(0.01	)		(0.04	)
Net earnings (loss) - diluted	7.03			1.75			4.79
Weighted average shares (in millions)
Basic	108.5			108.4			108.6
Diluted	109.2			109.1			109.4

Consolidated Statements of Operations - Unaudited

	Year Ended December 31,
	2022			2021
	(In $ millions, except share and per share data)
Net sales	9,673			8,537
Cost of sales	(7,293	)		(5,855	)
Gross profit	2,380			2,682
Selling, general and administrative expenses	(824	)		(633	)
Amortization of intangible assets	(62	)		(25	)
Research and development expenses	(112	)		(86	)
Other (charges) gains, net	(8	)		3
Foreign exchange gain (loss), net	(1	)		2
Gain (loss) on disposition of businesses and assets, net	5			3
Operating profit (loss)	1,378			1,946
Equity in net earnings (loss) of affiliates	220			146
Non-operating pension and other postretirement employee benefit (expense) income	17			106
Interest expense	(405	)		(91	)
Refinancing expense	—			(9	)
Interest income	69			8
Dividend income - equity investments	133			147
Other income (expense), net	9			(5	)
Earnings (loss) from continuing operations before tax	1,421			2,248
Income tax (provision) benefit	489			(330	)
Earnings (loss) from continuing operations	1,910			1,918
Earnings (loss) from operation of discontinued operations	(9	)		(27	)
Income tax (provision) benefit from discontinued operations	1			5
Earnings (loss) from discontinued operations	(8	)		(22	)
Net earnings (loss)	1,902			1,896
Net (earnings) loss attributable to noncontrolling interests	(8	)		(6	)
Net earnings (loss) attributable to Celanese Corporation	1,894			1,890
Amounts attributable to Celanese Corporation
Earnings (loss) from continuing operations	1,902			1,912
Earnings (loss) from discontinued operations	(8	)		(22	)
Net earnings (loss)	1,894			1,890
Earnings (loss) per common share - basic
Continuing operations	17.55			17.19
Discontinued operations	(0.07	)		(0.20	)
Net earnings (loss) - basic	17.48			16.99
Earnings (loss) per common share - diluted
Continuing operations	17.41			17.06
Discontinued operations	(0.07	)		(0.20	)
Net earnings (loss) - diluted	17.34			16.86
Weighted average shares (in millions)
Basic	108.4			111.2
Diluted	109.2			112.1

Consolidated Balance Sheets - Unaudited

	As of December 31, 2022			As of December 31, 2021
	(In $ millions)
ASSETS
Current Assets
Cash and cash equivalents	1,508			536
Trade receivables - third party and affiliates, net	1,379			1,161
Non-trade receivables, net	675			506
Inventories	2,808			1,524
Other assets	241			80
Total current assets	6,611			3,807
Investments in affiliates	1,062			823
Property, plant and equipment, net	5,584			4,193
Operating lease right-of-use assets	413			236
Deferred income taxes	808			248
Other assets	547			521
Goodwill	7,142			1,412
Intangible assets, net	4,105			735
Total assets	26,272			11,975
LIABILITIES AND EQUITY
Current Liabilities
Short-term borrowings and current installments of long-term debt - third party and affiliates	1,306			791
Trade payables - third party and affiliates	1,518			1,160
Other liabilities	1,201			473
Income taxes payable	43			81
Total current liabilities	4,068			2,505
Long-term debt, net of unamortized deferred financing costs	13,373			3,176
Deferred income taxes	1,242			555
Uncertain tax positions	322			280
Benefit obligations	411			558
Operating lease liabilities	364			200
Other liabilities	387			164
Commitments and Contingencies
Stockholders' Equity
Treasury stock, at cost	(5,491	)		(5,492	)
Additional paid-in capital	372			333
Retained earnings	11,274			9,677
Accumulated other comprehensive income (loss), net	(518	)		(329	)
Total Celanese Corporation stockholders' equity	5,637			4,189
Noncontrolling interests	468			348
Total equity	6,105			4,537
Total liabilities and equity	26,272			11,975

Non-US GAAP Financial Measures and Supplemental Information

February 23, 2023

In this document, the terms the "Company," "we" and "our" refer to Celanese Corporation and its subsidiaries on a consolidated basis.

Purpose

The purpose of this document is to provide information of interest to investors, analysts and other parties including supplemental financial information and reconciliations and other information concerning our use of non-US GAAP financial measures. This document is updated quarterly.

Presentation

This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.

Use of Non-US GAAP Financial Measures

From time to time, management may publicly disclose certain numerical "non-GAAP financial measures" in the course of our earnings releases, financial presentations, earnings conference calls, investor and analyst meetings and otherwise. For these purposes, the Securities and Exchange Commission ("SEC") defines a "non-GAAP financial measure" as a numerical measure of historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that effectively exclude amounts, included in the most directly comparable measure calculated and presented in accordance with US GAAP, and vice versa for measures that include amounts, or are subject to adjustments that effectively include amounts, that are excluded from the most directly comparable US GAAP measure so calculated and presented. For these purposes, "GAAP" refers to generally accepted accounting principles in the United States.

Non-GAAP financial measures disclosed by management are provided as additional information to investors, analysts and other parties because the Company believes them to be important supplemental measures for assessing our financial and operating results and as a means to evaluate our financial condition and period-to-period comparisons. These non-GAAP financial measures should be viewed as supplemental to, and should not be considered in isolation or as alternatives to, net earnings (loss), operating profit (loss), operating margin, cash flow from operating activities (together with cash flow from investing and financing activities), earnings per share or any other US GAAP financial measure. These non-GAAP financial measures should be considered within the context of our complete audited and unaudited financial results for the given period, which are available on the Financial Information/Financial Document Library page of our website, investors.celanese.com. The definition and method of calculation of the non-GAAP financial measures used herein may be different from other companies' methods for calculating measures with the same or similar titles. Investors, analysts and other parties should understand how another company calculates such non-GAAP financial measures before comparing the other company's non-GAAP financial measures to any of our own. These non-GAAP financial measures may not be indicative of the historical operating results of the Company nor are they intended to be predictive or projections of future results.

Pursuant to the requirements of SEC Regulation G, whenever we refer to a non-GAAP financial measure, we will also present in this document, in the presentation itself or on a Form 8-K in connection with the presentation on the Financial Information/Financial Document Library page of our website, investors.celanese.com, to the extent practicable, the most directly comparable financial measure calculated and presented in accordance with GAAP, along with a reconciliation of the differences between the non-GAAP financial measure we reference and such comparable GAAP financial measure.

This document includes definitions and reconciliations of non-GAAP financial measures used from time to time by the Company.

Specific Measures Used

This document provides information about the following non-GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, operating profit (loss) attributable to Celanese Corporation, adjusted earnings per share, net debt, free cash flow and return on invested capital (adjusted). The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin and operating EBITDA margin is operating margin; for operating profit (loss) attributable to Celanese Corporation is operating profit (loss); for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; for net debt is total debt; for free cash flow is net cash provided by (used in) operations; and for return on invested capital (adjusted) is net earnings (loss) attributable to Celanese Corporation divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation stockholders' equity.

Definitions

• Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8). We believe that adjusted EBIT provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of unusual, non-operational or restructuring-related activities that affect comparability. Our management recognizes that adjusted EBIT has inherent limitations because of the excluded items. Adjusted EBIT is one of the measures management uses for planning and budgeting, monitoring and evaluating financial and operating results and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales. Adjusted EBIT margin has the same uses and limitations as Adjusted EBIT.
  
  
• Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. We believe that Operating EBITDA provides transparent and useful information to investors, analysts and other parties in evaluating our operating performance relative to our peer companies. Operating EBITDA margin is defined by the Company as Operating EBITDA divided by net sales. Operating EBITDA margin has the same uses and limitations as Operating EBITDA.
  
  
• Operating profit (loss) attributable to Celanese Corporation is defined by the Company as operating profit (loss), less earnings (loss) attributable to noncontrolling interests ("NCI"). We believe that operating profit (loss) attributable to Celanese Corporation provides transparent and useful information to management, investors, analysts and other parties in evaluating our core operational performance. Operating margin attributable to Celanese Corporation is defined by the Company as operating profit (loss) attributable to Celanese Corporation divided by net sales. Operating margin attributable to Celanese Corporation has the same uses and limitations as Operating profit (loss) attributable to Celanese Corporation.
  
  
• Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We believe that adjusted earnings per share provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of the above stated items that affect comparability and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
  
  Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
  
  
• Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for capital contributions from or distributions to Mitsui & Co., Ltd. ("Mitsui") related to our methanol joint venture, Fairway Methanol LLC ("Fairway"). We believe that free cash flow provides useful information to management, investors, analysts and other parties in evaluating the Company's liquidity and credit quality assessment because it provides an indication of the long-term cash generating ability of our business. Although we use free cash flow as a measure to assess the liquidity generated by our business, the use of free cash flow has important limitations, including that free cash flow does not reflect the cash requirements necessary to service our indebtedness, lease obligations, unconditional purchase obligations or pension and postretirement funding obligations. Free cash flow is not a measure of cash available for discretionary expenditures since the Company has certain debt service and finance lease payments that are not deducted from that measure.
  
  
• Net debt is defined by the Company as total debt less cash and cash equivalents. We believe that net debt provides useful information to management, investors, analysts and other parties in evaluating changes to the Company's capital structure and credit quality assessment.
  
  
• Return on invested capital (adjusted) is defined by the Company as adjusted EBIT, tax effected using the adjusted tax rate, divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation stockholders' equity. We believe that return on invested capital (adjusted) provides useful information to management, investors, analysts and other parties in order to assess our income generation from the point of view of our stockholders and creditors who provide us with capital in the form of equity and debt and whether capital invested in the Company yields competitive returns.
  

Supplemental Information

Supplemental Information we believe to be of interest to investors, analysts and other parties includes the following:

• Net sales for each of our business segments and the percentage increase or decrease in net sales attributable to price, volume, currency and other factors for each of our business segments.
  
  
• Cash dividends received from our equity investments.
  
  
• For those consolidated ventures in which the Company owns or is exposed to less than 100% of the economics, the outside stockholders' interests are shown as NCI. Beginning in 2014, this includes Fairway for which the Company's ownership percentage is 50%. Amounts referred to as "attributable to Celanese Corporation" are net of any applicable NCI.

Results Unaudited

The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.

Table 1 Adjusted EBIT and Operating EBITDA - Reconciliation of Non-GAAP Measures - Unaudited
	2022			Q4 '22			Q3 '22			Q2 '22			Q1 '22			2021			Q4 '21			Q3 '21			Q2 '21			Q1 '21
	(In $ millions)
Net earnings (loss) attributable to Celanese Corporation	1,894			767			191			434			502			1,890			524			506			538			322
(Earnings) loss from discontinued operations	8			1			1			6			—			22			4			13			4			1
Interest income	(69	)		(33	)		(34	)		(1	)		(1	)		(8	)		(1	)		(2	)		(4	)		(1	)
Interest expense	405			168			154			48			35			91			21			21			24			25
Refinancing expense	—			—			—			—			—			9			—			9			—			—
Income tax provision (benefit)	(489	)		(840	)		127			112			112			330			27			102			116			85
Certain Items attributable to Celanese Corporation (Table 8)	422			239			71			47			65			139			77			(1	)		13			50
Adjusted EBIT	2,171			302			510			646			713			2,473			652			648			691			482
Depreciation and amortization expense(1)	446			151			97			98			100			362			93			91			90			88
Operating EBITDA	2,617			453			607			744			813			2,835			745			739			781			570

	2022			Q4 '22			Q3 '22			Q2 '22			Q1 '22			2021			Q4 '21			Q3 '21			Q2 '21			Q1 '21
	(In $ millions)
Engineered Materials	13			2			3			4			4			9			4			2			1			2
Acetyl Chain	2			—			—			—			2			—			—			—			—			—
Other Activities(2)	1			—			—			1			—			—			—			—			—			—
Accelerated depreciation and amortization expense	16			2			3			5			6			9			4			2			1			2
Depreciation and amortization expense(1)	446			151			97			98			100			362			93			91			90			88
Total depreciation and amortization expense	462			153			100			103			106			371			97			93			91			90

______________________________
(1)	Excludes accelerated depreciation and amortization expense as detailed in the table above, which amounts are included in Certain Items above.
(2)	Other Activities includes corporate Selling, general and administrative ("SG&A") expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

Table 2 - Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited
	2022						Q4 '22						Q3 '22						Q2 '22						Q1 '22						2021						Q4 '21						Q3 '21						Q2 '21						Q1 '21
	(In $ millions, except percentages)
Operating Profit (Loss) / Operating Margin
Engineered Materials	429			10.7	%		25			2.0	%		114			12.3	%		166			17.5	%		124			13.6	%		411			15.1	%		67			9.5	%		91			13.3	%		123			18.0	%		130			20.2	%
Acetyl Chain(1)	1,447			25.2	%		204			18.0	%		312			22.3	%		428			27.5	%		503			30.4	%		1,875			31.8	%		539			33.9	%		529			33.0	%		540			35.2	%		267			22.9	%
Other Activities(2)	(498	)					(173	)					(118	)					(111	)					(96	)					(340	)					(89	)					(84	)					(96	)					(71	)
Total	1,378			14.2	%		56			2.4	%		308			13.4	%		483			19.4	%		531			20.9	%		1,946			22.8	%		517			22.7	%		536			23.7	%		567			25.8	%		326			18.1	%
Less: Net Earnings (Loss) Attributable to NCI(1)	8						2						2						2						2						6						2						1						2						1
Operating Profit (Loss) Attributable to Celanese Corporation	1,370			14.2	%		54			2.3	%		306			13.3	%		481			19.3	%		529			20.8	%		1,940			22.7	%		515			22.6	%		535			23.6	%		565			25.7	%		325			18.1	%
Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation
Engineered Materials	429			10.7	%		25			2.0	%		114			12.3	%		166			17.5	%		124			13.6	%		411			15.1	%		67			9.5	%		91			13.3	%		123			18.0	%		130			20.2	%
Acetyl Chain(1)	1,439			25.1	%		202			17.8	%		310			22.2	%		426			27.3	%		501			30.3	%		1,869			31.7	%		537			33.8	%		528			33.0	%		538			35.0	%		266			22.8	%
Other Activities(2)	(498	)					(173	)					(118	)					(111	)					(96	)					(340	)					(89	)					(84	)					(96	)					(71	)
Total	1,370			14.2	%		54			2.3	%		306			13.3	%		481			19.3	%		529			20.8	%		1,940			22.7	%		515			22.6	%		535			23.6	%		565			25.7	%		325			18.1	%
Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation
Engineered Materials	207						35						70						53						49						127						30						40						32						25
Acetyl Chain	143						30						34						39						40						154						36						36						39						43
Other Activities(2)	12						1						4						1						6						7						1						1						4						1
Total	362						66						108						93						95						288						67						77						75						69
Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation
Engineered Materials	—						—						—						—						—						—						—						—						—						—
Acetyl Chain	—						—						—						—						—						—						—						—						—						—
Other Activities(2)	17						(57	)					25						25						24						106						(7	)					37						38						38
Total	17						(57	)					25						25						24						106						(7	)					37						38						38
Certain Items Attributable to Celanese Corporation (Table 8)
Engineered Materials	143						78						22						5						38						33						16						6						6						5
Acetyl Chain	27						10						5						10						2						33						1						(1	)					(1	)					34
Other Activities(2)	252						151						44						32						25						73						60						(6	)					8						11
Total	422						239						71						47						65						139						77						(1	)					13						50
Adjusted EBIT / Adjusted EBIT Margin
Engineered Materials	779			19.4	%		138			11.2	%		206			22.2	%		224			23.6	%		211			23.2	%		571			21.0	%		113			16.0	%		137			20.0	%		161			23.6	%		160			24.8	%
Acetyl Chain	1,609			28.0	%		242			21.3	%		349			25.0	%		475			30.5	%		543			32.9	%		2,056			34.9	%		574			36.1	%		563			35.1	%		576			37.5	%		343			29.4	%
Other Activities(2)	(217	)					(78	)					(45	)					(53	)					(41	)					(154	)					(35	)					(52	)					(46	)					(21	)
Total	2,171			22.4	%		302			12.9	%		510			22.2	%		646			26.0	%		713			28.1	%		2,473			29.0	%		652			28.7	%		648			28.6	%		691			31.4	%		482			26.8	%

______________________________
(1)	Net earnings (loss) attributable to NCI is included within the Acetyl Chain segment.
(2)	Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

Table 2 - Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited (cont.)
	2022						Q4 '22						Q3 '22						Q2 '22						Q1 '22						2021						Q4 '21						Q3 '21						Q2 '21						Q1 '21
	(In $ millions, except percentages)
Depreciation and Amortization Expense(1)
Engineered Materials	213						90						40						41						42						135						35						33						34						33
Acetyl Chain	211						52						53						52						54						210						53						54						52						51
Other Activities(2)	22						9						4						5						4						17						5						4						4						4
Total	446						151						97						98						100						362						93						91						90						88
Operating EBITDA / Operating EBITDA Margin
Engineered Materials	992			24.7	%		228			18.4	%		246			26.5	%		265			28.0	%		253			27.8	%		706			26.0	%		148			20.9	%		170			24.9	%		195			28.6	%		193			29.9	%
Acetyl Chain	1,820			31.7	%		294			25.9	%		402			28.8	%		527			33.8	%		597			36.1	%		2,266			38.4	%		627			39.4	%		617			38.5	%		628			40.9	%		394			33.8	%
Other Activities(2)	(195	)					(69	)					(41	)					(48	)					(37	)					(137	)					(30	)					(48	)					(42	)					(17	)
Total	2,617			27.1	%		453			19.3	%		607			26.4	%		744			29.9	%		813			32.0	%		2,835			33.2	%		745			32.7	%		739			32.6	%		781			35.5	%		570			31.7	%

______________________________
(1)	Excludes accelerated depreciation and amortization expense, which amounts are included in Certain Items above. See Table 1 for details.
(2)	Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

Table 3 Adjusted Earnings (Loss) per Share - Reconciliation of a Non-GAAP Measure - Unaudited
	2022						Q4 '22						Q3 '22						Q2 '22						Q1 '22						2021					Q4 '21					Q3 '21					Q2 '21					Q1 '21
				per share						per share						per share						per share						per share						per share					per share					per share					per share					per share
	(In $ millions, except per share data)
Earnings (loss) from continuing operations attributable to Celanese Corporation	1,902			17.41			768			7.03			192			1.76			440			4.03			502			4.61			1,912			17.06		528			4.83		519			4.67		542			4.81		323			2.83
Income tax provision (benefit)	(489	)					(840	)					127						112						112						330					27					102					116					85
Earnings (loss) from continuing operations before tax	1,413						(72	)					319						552						614						2,242					555					621					658					408
Certain Items attributable to Celanese Corporation (Table 8)	422						239						71						47						65						139					77					(1	)				13					50
Refinancing and related expenses	158			(1)			14			(1)			104			(1)			26			(1)			14			(1)			9					—					9					—					—
Adjusted earnings (loss) from continuing operations before tax	1,993						181						494						625						693						2,390					632					629					671					458
Income tax (provision) benefit on adjusted earnings(2)	(259	)					(24	)					(64	)					(81	)					(90	)					(359	)				(95	)				(94	)				(105	)				(64	)
Adjusted earnings (loss) from continuing operations(3)	1,734			15.88			157			1.44			430			3.94			544			4.99			603			5.54			2,031			18.12		537			4.91		535			4.82		566			5.02		394			3.46
	Diluted shares (in millions)(4)
Weighted average shares outstanding	108.4						108.5						108.4						108.4						108.2						111.2					108.6					110.5					112.3					113.5
Incremental shares attributable to equity awards	0.8						0.7						0.7						0.7						0.7						0.9					0.8					0.5					0.5					0.5
Total diluted shares	109.2						109.2						109.1						109.1						108.9						112.1					109.4					111.0					112.8					114.0

______________________________
(1)	Includes net interest expense and certain fees related to debt issued as part of our acquisition of a majority of the Mobility & Materials business ("M&M Business") of DuPont de Nemours, Inc.
(2)	Calculated using adjusted effective tax rates (Table 3a) as follows:

	2022					Q4 '22					Q3 '22					Q2 '22					Q1 '22					2021					Q4 '21					Q3 '21					Q2 '21					Q1 '21
Adjusted effective tax rate	13					13					13					13					13					15					15					15					16					14

______________________________
(3)	Excludes the immediate recognition of actuarial gains and losses and the impact of actual vs. expected plan asset returns.

		Actual Plan Asset Returns			Expected Plan Asset Returns
		(In percentages)
Q4 '22 & 2022		(18.4	)		5.4
Q4 '21 & 2021		1.1			6.3

______________________________
(4)	Potentially dilutive shares are included in the adjusted earnings per share calculation when adjusted earnings are positive.

Table 3a Adjusted Tax Rate - Reconciliation of a Non-GAAP Measure - Unaudited
	Actual
	2022			2021
	(In percentages)
US GAAP annual effective tax rate	(34	)		15
Discrete quarterly recognition of GAAP items(1)	(6	)		(2	)
Tax impact of other charges and adjustments(2)	9			(1	)
Utilization of foreign tax credits	—			(1	)
Changes in valuation allowances, excluding impact of other charges and adjustments(3)	(1	)		3
Other, includes effect of discrete current year transactions(4)(5)	45			1
Adjusted tax rate	13			15

______________________________
Note: As part of the year-end reconciliation, we updated the reconciliation of the GAAP effective tax rate for actual results.
(1)	Such as changes in tax laws (including US tax reform), deferred taxes on outside basis differences, changes in uncertain tax positions and prior year audit adjustments.
(2)	Reflects the tax impact on pre-tax adjustments presented in Certain Items (Table 8), which are excluded from pre-tax income for adjusted earnings per share purposes.
(3)	Reflects changes in valuation allowances related to changes in judgment regarding the realizability of deferred tax assets or current year operations, excluding other charges and adjustments.
(4)	Includes tax impacts related to full-year actual tax opportunities and related costs.
(5)	Includes the reversal of 2022 U.S. GAAP deferred tax benefits related to non-recurring internal restructuring transactions related to the M&M acquisition, to centralize ownership of intellectual property with the business and to facilitate future deployment of cash to service acquisition indebtedness. Certain benefits of the internal restructuring will be realized in future periods for adjusted earnings purposes.

Table 4 Net Sales by Segment - Unaudited
	2022			Q4 '22			Q3 '22			Q2 '22			Q1 '22			2021			Q4 '21			Q3 '21			Q2 '21			Q1 '21
	(In $ millions)
Engineered Materials	4,024			1,237			929			948			910			2,718			707			684			682			645
Acetyl Chain	5,743			1,135			1,397			1,559			1,652			5,894			1,590			1,602			1,535			1,167
Intersegment eliminations(1)	(94	)		(24	)		(25	)		(21	)		(24	)		(75	)		(22	)		(20	)		(19	)		(14	)
Net sales	9,673			2,348			2,301			2,486			2,538			8,537			2,275			2,266			2,198			1,798

___________________________
(1)	Includes intersegment sales primarily related to the Acetyl Chain.

Table 4a Factors Affecting Segment Net Sales Sequentially - Unaudited
Three Months Ended December 31, 2022 Compared to Three Months Ended September 30, 2022
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	34			(1	)		—			—			33		(1)
Acetyl Chain	(9	)		(10	)		—			—			(19	)
Total Company	8			(6	)		—			—			2

Three Months Ended September 30, 2022 Compared to Three Months Ended June 30, 2022
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	(1	)		2			(3	)		—			(2	)
Acetyl Chain	(3	)		(5	)		(2	)		—			(10	)
Total Company	(2	)		(3	)		(2	)		—			(7	)

Three Months Ended June 30, 2022 Compared to Three Months Ended March 31, 2022
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	1			6			(3	)		—			4
Acetyl Chain	(6	)		2			(2	)		—			(6	)
Total Company	(2	)		2			(2	)		—			(2	)

Three Months Ended March 31, 2022 Compared to Three Months Ended December 31, 2021
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	23			7			(1	)		—			29
Acetyl Chain	7			(3	)		—			—			4
Total Company	12			1			(1	)		—			12

________________________
(1)	2022 includes the effect of the acquisition of the majority of the M&M Business.

Three Months Ended December 31, 2021 Compared to Three Months Ended September 30, 2021
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	(1	)		5			(1	)		—			3		(2)
Acetyl Chain	(8	)		8			(1	)		—			(1	)
Total Company	(7	)		8			(1	)		—			—

Three Months Ended September 30, 2021 Compared to Three Months Ended June 30, 2021
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	(2	)		3			(1	)		—			—
Acetyl Chain	2			3			(1	)		—			4
Total Company	1			3			(1	)		—			3

Three Months Ended June 30, 2021 Compared to Three Months Ended March 31, 2021
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	(1	)		7			—			—			6
Acetyl Chain	7			24			—			—			31
Total Company	4			18			—			—			22

Three Months Ended March 31, 2021 Compared to Three Months Ended December 31, 2020
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	6			6			1			—			13
Acetyl Chain	(8	)		20			1			—			13
Total Company	(3	)		15			1			—			13

________________________
(2)	2021 includes the effect of the acquisition of the Santoprene™ thermoplastic vulcanizates elastomers business.

Table 4b Factors Affecting Segment Net Sales Year Over Year - Unaudited
Three Months Ended December 31, 2022 Compared to Three Months Ended December 31, 2021
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	67			17			(9	)		—			75
Acetyl Chain	(12	)		(14	)		(3	)		—			(29	)
Total Company	13			(5	)		(5	)		—			3

Three Months Ended September 30, 2022 Compared to Three Months Ended September 30, 2021
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	23			25			(12	)		—			36
Acetyl Chain	(10	)		2			(5	)		—			(13	)
Total Company	(2	)		9			(5	)		—			2

Three Months Ended June 30, 2022 Compared to Three Months Ended June 30, 2021
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	24			24			(9	)		—			39
Acetyl Chain	(5	)		11			(4	)		—			2
Total Company	3			14			(4	)		—			13

Three Months Ended March 31, 2022 Compared to Three Months Ended March 31, 2021
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	20			25			(4	)		—			41
Acetyl Chain	7			38			(3	)		—			42
Total Company	12			32			(3	)		—			41

Three Months Ended December 31, 2021 Compared to Three Months Ended December 31, 2020
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	5			20			(1	)		—			24
Acetyl Chain	(6	)		60			(1	)		—			53
Total Company	(2	)		46			(1	)		—			43

Three Months Ended September 30, 2021 Compared to Three Months Ended September 30, 2020
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	11			17			2			—			30
Acetyl Chain	9			67			2			—			78
Total Company	10			50			1			—			61

Three Months Ended June 30, 2021 Compared to Three Months Ended June 30, 2020
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	43			11			8			—			62
Acetyl Chain	19			69			9			—			97
Total Company	31			50			3			—			84

Three Months Ended March 31, 2021 Compared to Three Months Ended March 31, 2020
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	7			2			6			—			15
Acetyl Chain	—			22			5			—			27
Total Company	5			14			4			—			23

Table 4c Factors Affecting Segment Net Sales Year Over Year - Unaudited
Year Ended December 31, 2022 Compared to Year Ended December 31, 2021
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	33			23			(8	)		—			48
Acetyl Chain	(6	)		6			(3	)		—			(3	)
Total Company	6			11			(4	)		—			13

Year Ended December 31, 2021 Compared to Year Ended December 31, 2020
	Volume			Price			Currency			Other			Total
	(In percentages)
Engineered Materials	15			12			4			—			31
Acetyl Chain	5			54			3			—			62
Total Company	10			39			2			—			51

Table 5 Free Cash Flow - Reconciliation of a Non-GAAP Measure - Unaudited
	2022			Q4 '22			Q3 '22			Q2 '22			Q1 '22			2021			Q4 '21			Q3 '21			Q2 '21			Q1 '21
	(In $ millions, except percentages)
Net cash provided by (used in) investing activities	(11,141	)		(10,713	)		(143	)		(136	)		(149	)		(1,119	)		(1,286	)		(108	)		177			98
Net cash provided by (used in) financing activities	10,290			1,944			8,600			(159	)		(95	)		(1,042	)		(99	)		(228	)		(344	)		(371	)
Net cash provided by (used in) operating activities	1,819			541			467			495			316			1,757			584			630			427			116
Capital expenditures on property, plant and equipment	(543	)		(143	)		(139	)		(124	)		(137	)		(467	)		(163	)		(102	)		(110	)		(92	)
Distributions to NCI	(13	)		(3	)		(3	)		(3	)		(4	)		(27	)		(6	)		(8	)		(8	)		(5	)
Free cash flow(1)	1,263			395			325			368			175			1,263			415			520			309			19
Net sales	9,673			2,348			2,301			2,486			2,538			8,537			2,275			2,266			2,198			1,798
Free cash flow as % of Net sales	13.1	%		16.8	%		14.1	%		14.8	%		6.9	%		14.8	%		18.2	%		22.9	%		14.1	%		1.1	%

______________________________
(1)	Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operating activities, less capital expenditures on property, plant and equipment, and adjusted for capital contributions or distributions to Mitsui related to our joint venture, Fairway.

Table 6 Cash Dividends Received - Unaudited
	2022			Q4 '22			Q3 '22			Q2 '22			Q1 '22			2021			Q4 '21			Q3 '21			Q2 '21			Q1 '21
	(In $ millions)
Dividends from equity method investments	217			82			27			82			26			112			51			8			18			35
Dividends from equity investments without readily determinable fair values	133			30			30			36			37			147			33			35			37			42
Total	350			112			57			118			63			259			84			43			55			77

Table 7 Net Debt - Reconciliation of a Non-GAAP Measure - Unaudited
	2022			Q4 '22			Q3 '22			Q2 '22			Q1 '22			2021			Q4 '21			Q3 '21			Q2 '21			Q1 '21
	(In $ millions)
Short-term borrowings and current installments of long-term debt - third party and affiliates	1,306			1,306			977			809			860			791			791			103			500			497
Long-term debt, net of unamortized deferred financing costs	13,373			13,373			11,360			3,022			3,132			3,176			3,176			3,724			3,156			3,135
Total debt	14,679			14,679			12,337			3,831			3,992			3,967			3,967			3,827			3,656			3,632
Cash and cash equivalents	(1,508	)		(1,508	)		(9,671	)		(783	)		(605	)		(536	)		(536	)		(1,340	)		(1,054	)		(791	)
Net debt	13,171			13,171			2,666			3,048			3,387			3,431			3,431			2,487			2,602			2,841

Table 8 Certain Items - Unaudited
The following Certain Items attributable to Celanese Corporation are included in Net earnings (loss) and are adjustments to non-GAAP measures:
	2022			Q4 '22			Q3 '22			Q2 '22			Q1 '22			2021			Q4 '21			Q3 '21				Q2 '21			Q1 '21			Income Statement Classification
	(In $ millions)
Exit and shutdown costs	52			2			14			29			7			18			8			7				5			(2	)		Cost of sales / SG&A / Other (charges) gains, net / Gain (loss) on disposition of businesses and assets, net / Non-operating pension and other postretirement employee benefit (expense) income
Asset impairments	13			2			12			(1	)		—			2			—			—				1			1			Cost of sales / Other (charges) gains, net
Impact from plant incidents and natural disasters(1)	17			17			—			—			—			41			—			—				—			41			Cost of sales
Mergers, acquisitions and dispositions	267			138			44			29			56			29			19			4				6			—			Cost of sales / SG&A
Actuarial (gain) loss on pension and postretirement plans	80			80			—			—			—			43			43			—				—			—			Cost of sales / SG&A / Non-operating pension and other postretirement employee benefit (expense) income
Legal settlements and commercial disputes	3			—			1			—			2			16			4			2				1			9			Cost of sales / SG&A / Other (charges) gains, net
Other	(10	)		—			—			(10	)		—			(10	)		3			(14	)	(2)		—			1			Cost of sales / SG&A / Gain (loss) on disposition of businesses and assets, net
Certain Items attributable to Celanese Corporation	422			239			71			47			65			139			77			(1	)			13			50

___________________________
(1)	Primarily associated with Winter Storm Uri.
(2)	Primarily associated with the sale of our Spondon site.

Table 9 Return on Invested Capital (Adjusted) - Presentation of a Non-GAAP Measure - Unaudited
					2022							2021
					(In $ millions, except percentages)							(In $ millions, except percentages)
Net earnings (loss) attributable to Celanese Corporation					1,894							1,890
Adjusted EBIT (Table 1)					2,171							2,473
Adjusted effective tax rate (Table 3a)					13	%						15	%
Adjusted EBIT tax effected					1,889							2,102
	2022		2021		Average			2021		2020		Average
	(In $ millions, except percentages)
Short-term borrowings and current installments of long-term debt - third parties and affiliates	1,306		791		1,049			791		496		644
Long-term debt, net of unamortized deferred financing costs	13,373		3,176		8,275			3,176		3,227		3,202
Celanese Corporation stockholders' equity	5,637		4,189		4,913			4,189		3,526		3,858
Invested capital					14,237							7,704
Return on invested capital (adjusted)					13.3	%						27.3	%
Net earnings (loss) attributable to Celanese Corporation as a percentage of invested capital					13.3	%						24.5	%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005821/en/

Investor Relations

Brandon Ayache

Phone: +1 972 443 8509

brandon.ayache@celanese.com

Media - U.S.

Brian Bianco

Phone: +1 972 443 4400

media@celanese.com

Media - Europe

Petra Czugler

Phone: +49 69 45009 1206

petra.czugler@celanese.com

Source: Celanese Corporation

FAQ

What were Celanese's 2022 earnings per share results?

Celanese reported a GAAP diluted EPS of $17.41 and adjusted EPS of $15.88 for the full year 2022.

How did the acquisition of DuPont's Mobility & Materials business impact Celanese?

The acquisition significantly contributed to Celanese's performance in the last two months of 2022, enhancing its market position in specialty materials.

What were the net sales figures for Celanese in 2022?

Celanese achieved record net sales of $9.7 billion in 2022, reflecting a 13% increase over the previous year.

What challenges did Celanese face in the fourth quarter of 2022?

In Q4 2022, Celanese encountered issues such as accelerated destocking and reduced demand in Asia.

What is the outlook for Celanese's earnings in Q1 2023?

Celanese anticipates adjusted EPS between $1.50 to $1.75 in Q1 2023, suggesting potential sequential earnings improvement.